Related Experiment Video
Updated: Dec 6, 2025
A Unified Methodological Framework for Vestibular Schwannoma Research
Published on: June 20, 2017
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Sheila Mansouri1, Suganth Suppiah1, Yasin Mamatjan1
1Princess Margaret Cancer Center and MacFeeters-Hamilton Center for Neuro-Oncology Research, University Health Network, Wilkins Family Chair in Brain Tumor Research, 14-701 PMCRT, 101 College St, Toronto, ON, M5G 1L7, Canada.
Abstract:
Schwannomatosis (SWNTS) is a genetic cancer predisposition syndrome that manifests as multiple and often painful neuronal tumors called schwannomas (SWNs). While germline mutations in SMARCB1 or LZTR1, plus somatic mutations in NF2 and loss of heterozygosity in chromosome 22q have been identified in a subset of patients, little is known about the epigenomic and genomic alterations that drive SWNTS-related SWNs (SWNTS-SWNs) in a majority of the cases. We performed multiplatform genomic analysis and established the molecular signature of SWNTS-SWNs. We show that SWNTS-SWNs harbor distinct genomic features relative to the histologically identical non-syndromic sporadic SWNs (NS-SWNS). We demonstrate the existence of four distinct DNA methylation subgroups of SWNTS-SWNs that are associated with specific transcriptional programs and tumor location. We show several novel recurrent non-22q deletions and structural rearrangements. We detected the SH3PXD2A-HTRA1 gene fusion in SWNTS-SWNs, with predominance in LZTR1-mutant tumors. In addition, we identified specific genetic, epigenetic, and actionable transcriptional programs associated with painful SWNTS-SWNs including PIGF, VEGF, MEK, and MTOR pathways, which may be harnessed for management of this syndrome.
Insights
Schwannomatosis (SWNTS) involves multiple schwannomas. This study reveals distinct genomic and epigenomic features of SWNTS-related schwannomas, identifying new therapeutic targets for managing this genetic cancer predisposition syndrome.
Area of Science:
- Genomics
- Epigenomics
- Cancer Biology
Background:
- Schwannomatosis (SWNTS) is a rare genetic disorder characterized by multiple schwannomas.
- Known genetic drivers (SMARCB1, LZTR1, NF2) explain only a subset of SWNTS cases.
- The molecular underpinnings of most SWNTS-related schwannomas (SWNTS-SWNs) remain largely unknown.
Purpose of the Study:
- To elucidate the distinct genomic and epigenomic landscape of SWNTS-SWNs.
- To identify molecular signatures differentiating SWNTS-SWNs from sporadic schwannomas (NS-SWNS).
- To uncover potential therapeutic targets for SWNTS management.
Main Methods:
- Multiplatform genomic and epigenomic analyses.
- Comparative analysis of SWNTS-SWNs and NS-SWNS.
- DNA methylation profiling, transcriptional analysis, and detection of gene fusions/rearrangements.
Main Results:
- SWNTS-SWNs exhibit unique genomic features compared to NS-SWNS.
- Four distinct DNA methylation subgroups identified within SWNTS-SWNs, correlating with transcriptional profiles and tumor location.
- Novel non-22q deletions, structural rearrangements, and the SH3PXD2A-HTRA1 gene fusion (particularly in LZTR1-mutant tumors) were detected.
- Specific genetic and epigenetic programs linked to painful SWNTS-SWNs, including PIGF, VEGF, MEK, and MTOR pathways.
Conclusions:
- SWNTS-SWNs possess a distinct molecular signature differentiating them from sporadic schwannomas.
- The identified methylation subgroups and pathways offer insights into SWNTS pathogenesis.
- Targetable pathways (PIGF, VEGF, MEK, MTOR) present opportunities for novel therapeutic strategies in managing painful schwannomatosis.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024